HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2004.042192v1 51/5/856    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Cheng, Z.-Z. Articles by Jokiranta, T. S. Search for Related Content PubMed PubMed Citation Articles by Cheng, Z.-Z. Articles by Jokiranta, T. S. Related Collections Cancer Diagnostics (since 2002) Proteomics and Protein Markers

Complement Factor H as a Marker for Detection of Bladder Cancer

¹ Department of Bacteriology and Immunology, Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
² CellExSys, Seattle, WA.
³ Molecular Immunobiology Group and Department for Infection Biology, Hans Knöll Institute for Natural Products Research, Jena, Germany.
⁴ CuraGen Corporation, Branford, CT.
⁵ Division of Urology, Clinic of Surgery, Seinäjoki Central Hospital, Seinäjoki, Finland.

^aAddress correspondence to this author at: Haartman Institute, University of Helsinki, PO Box 21, Helsinki FIN-00014, Finland. Fax 358-9-1912-6382; e-mail sakari.jokiranta{at}helsinki.fi.

Background: The BTA TRAK^TM and BTA stat^TM tests for bladder cancer use monoclonal antibodies (mAbs) X13.2 and X52.1 to detect factor H (FH)-related material in urine. The exact ligands remain unknown.

Methods: Western blot analyses of purified FH, recombinant factor H-related protein 1 (FHR-1), and serum and urine samples were used to identify the ligands of X13.2 and X52.1. Recombinant FH constructs were used to identify the target sites of X13.2 and X52.1. To analyze whether natural ligands of FH could compete with its recognition by the capture mAb X52.1, we used surface plasmon resonance analysis. The role of the ligands of X52.1 in the BTA TRAK assay was tested with use of purified proteins and FH-depleted samples.

Results: X13.2 bound to domain 3 of FH and FH-like protein 1, whereas X52.1 bound to domain 18 of FH and to FHR-1. Using specific FH depletion from a bladder cancer patient’s urine and purified FH, we demonstrated that FH is the ligand recognized by the BTA TRAK test. By contrast, FHR-1 in urine reduced the FH-dependent test signal.

Conclusions: FH is a tumor marker for bladder cancer. To reveal the presence of bladder cancer, the BTA TRAK assay detects FH, whereas FHR-1 is able to partly inhibit this detection. This indicates a special mechanism for a diagnostic immunoassay based on the combined effect of simultaneous positive and negative signals in a single sample.

The following articles in journals at HighWire Press have cited this article:

				N. Cheung, A. Shankar, R. Klein, A. R. Folsom, D. J. Couper, T. Y. Wong, and for the Atherosclerosis Risk in Communities (ARIC) Age-Related Macular Degeneration and Cancer Mortality in the Atherosclerosis Risk in Communities Study Arch Ophthalmol, September 1, 2007; 125(9): 1241 - 1247. [Abstract] [Full Text] [PDF]

				V. P. Ferreira, A. P. Herbert, H. G. Hocking, P. N. Barlow, and M. K. Pangburn Critical Role of the C-Terminal Domains of Factor H in Regulating Complement Activation at Cell Surfaces J. Immunol., November 1, 2006; 177(9): 6308 - 6316. [Abstract] [Full Text] [PDF]